Trial Profile
A prospective, multicenter, observational post-authorization safety study to evaluate the long term safety profile of Lemtrada (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 29 Jan 2016 New trial record